Assetmark Inc. boosted its position in shares of VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report) by 5.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,491 shares of the company’s stock after acquiring an additional 354 shares during the period. Assetmark Inc. owned 0.09% of VanEck Pharmaceutical ETF worth $617,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently bought and sold shares of PPH. Optimum Investment Advisors acquired a new position in shares of VanEck Pharmaceutical ETF during the second quarter valued at about $27,000. GPS Wealth Strategies Group LLC bought a new stake in shares of VanEck Pharmaceutical ETF during the second quarter valued at approximately $42,000. CWM LLC bought a new stake in shares of VanEck Pharmaceutical ETF during the second quarter valued at approximately $55,000. International Assets Investment Management LLC acquired a new position in VanEck Pharmaceutical ETF in the second quarter valued at approximately $86,000. Finally, Comerica Bank lifted its holdings in VanEck Pharmaceutical ETF by 39.4% in the first quarter. Comerica Bank now owns 1,337 shares of the company’s stock valued at $121,000 after buying an additional 378 shares during the period.
VanEck Pharmaceutical ETF Price Performance
Shares of NASDAQ PPH opened at $86.59 on Friday. The company’s 50 day simple moving average is $93.68 and its 200 day simple moving average is $92.98. The firm has a market capitalization of $639.90 million, a P/E ratio of 21.04 and a beta of 0.72. VanEck Pharmaceutical ETF has a fifty-two week low of $76.39 and a fifty-two week high of $99.51.
About VanEck Pharmaceutical ETF
The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.
See Also
- Five stocks we like better than VanEck Pharmaceutical ETF
- What is the Shanghai Stock Exchange Composite Index?
- How Whitestone REIT Is Transforming Sun Belt Retail Growth
- What is a buyback in stocks? A comprehensive guide for investors
- Top-Performing Non-Leveraged ETFs This Year
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
Want to see what other hedge funds are holding PPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report).
Receive News & Ratings for VanEck Pharmaceutical ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Pharmaceutical ETF and related companies with MarketBeat.com's FREE daily email newsletter.
